Press Releases

CAMBRIDGE, Mass., May 01, 2008 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it will webcast its corporate presentation at the Deutsche Bank 33rd Annual Health Care Conference on Monday, May 5, 2008 at 1:20 p.m. EDT.

CAMBRIDGE, Mass., Apr 28, 2008 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it will webcast its corporate presentation at the 2008 Morgan Stanley Global Healthcare Unplugged Conference on Wednesday, April 30, 2008 at 4:20 p.m. EDT.

-Interim results to be presented in late-breaker poster
presentation at EASL on April 24-

-Significant early on-treatment viral response from patients who
previously failed therapy-

- High sustained virologic response (SVR) rates of 61% in PROVE 1
and 68% in PROVE 2 with 24-week telaprevir-based treatment regimen -

- Telaprevir first and only investigational HCV protease inhibitor
in Phase 3, ADVANCE trial underway -

--Telaprevir data in HCV patients who failed current therapies to
be presented at EASL--

--Pharmacokinetic analyses in HCV patients show potential for
twice-daily dosing of telaprevir--

--VX-770 for cystic fibrosis to advance based on positive results
reported in March 2008--

CAMBRIDGE, Mass., Apr 07, 2008 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it will webcast its corporate presentation at the Canaccord|Adams Hepatitis C Conference on Wednesday, April 9, 2008 at 4:00 p.m. EDT.

CAMBRIDGE, Mass., Apr 07, 2008 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will announce its first quarter 2008 financial results on Monday, April 21, 2008 after the financial markets close. The Company will host a conference call at 5:00 p.m. EDT.

CAMBRIDGE, Mass., Mar 31, 2008 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that data related to its investigational hepatitis C protease inhibitor telaprevir will be featured in a late-breaker poster presentation during the 43rd Annual Meeting of the

--Interim analysis of 14-day study of VX-770 shows a significant
improvement in lung function --

--Lung function data supported by corresponding improvements in
disease-related biomarkers--

--Results to be shared with health authorities in order to
identify the most rapid path forward --

CAMBRIDGE, Mass., Mar 14, 2008 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it will webcast its corporate presentation at the Cowen and Company 28th Annual Health Care Conference on Wednesday, March 19, 2008 at 8:00 a.m. EDT.

- First hepatitis C protease inhibitor to begin Phase 3 clinical development - - Trial designed to confirm potential of telaprevir to increase sustained viral response (SVR) rates with 24-week treatment duration -

CAMBRIDGE, Mass., Feb 29, 2008 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq:VRTX) today announced that the Company will participate in an HCV panel, entitled: "HCV: Protease Inhibitors and Beyond" at Susquehanna Financial Group's Second Annual SIGnificant Investment Options in

CAMBRIDGE, Mass., Feb 19, 2008 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the completion of its public offerings of 6,900,000 shares of common stock, including 900,000 shares purchased by the underwriters pursuant to their over-allotment option, and $287.5

Vertex Pharmaceuticals Announces Exercise of Over-Allotment Options by Underwriters of its Concurrent Public Offerings of Common Stock and Convertible Senior Subordinated Notes CAMBRIDGE, Mass., Feb 13, 2008 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that

CAMBRIDGE, Mass., Feb 12, 2008 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it has entered into an agreement to sell 6,000,000 shares of its common stock in an underwritten offering at a price to the public of $17.14 per share.

-- Focused on first-to-market opportunity with HCV protease
inhibitor telaprevir --

-- Additional drug candidates directed at HCV, cystic fibrosis and
immune-mediated diseases--

CAMBRIDGE, Mass., Feb 11, 2008 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it intends to offer, subject to market and other conditions, 6,000,000 shares of its common stock in an underwritten public offering under an automatically effective shelf

CAMBRIDGE, Mass., Feb 08, 2008 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it will webcast its corporate presentation at the BIO CEO & Investor Conference 2008 on Tuesday, February 12, 2008 at 10:15 a.m. EST.

CAMBRIDGE, Mass., Jan 31, 2008 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it will webcast its corporate presentation at the 2008 Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference on Tuesday, February 5, 2008 at 11:40 a.m.

CAMBRIDGE, Mass., Jan 28, 2008 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will announce its fourth quarter and full year 2007 financial results on Monday, February 11, 2008 after the financial markets close. The Company will host a conference call at 5:00 p.m. EST.